CNBI:OTC-China BCT Pharmacy Group, Inc (USD)

COMMON STOCK | Pharmaceutical Retailers | OTC

Last Closing Price

USD 0.05

Change

0.00 (0.00)%

Market Cap

USD 1.88M

Volume

10.00

Average Target Price

N/A
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

China BCT Pharmacy Group, Inc., through its subsidiaries, operates as an integrated pharmaceutical company in the People's Republic of China. It operates through three segments: Pharmaceutical Distribution, Retail Pharmacy, and Manufacturing Pharmacy. The Pharmaceutical Distribution segment purchases pharmaceutical products from suppliers and distributes them to hospitals, retail drug stores, other pharmaceutical wholesalers, clinics, medical centers, and individuals. It offers approximately 8,000 pharmaceutical and healthcare products, including branded and generic prescription medicines, over-the counter medicines, and Western and Chinese medicines, as well as personal care products and medical supplies, Chinese herbs, and medical instruments. The Retail Pharmacy segment operates a retail pharmacy network of 196 directly owned stores, primarily in Guangxi province under the Baicaotang name. The retail stores provide professional pharmaceutical services, and supply various medicines, such as prescription medicines, over-the-counter medicines, Chinese herbal medicine, roughly processed Chinese herbal medicine, family planning products, and other pharmaceutical and healthcare products. The Manufacturing Pharmacy segment manufactures and sells generic and clinic drugs, such as traditional anti-inflammatory and antibacterial drugs, cancer treatment drugs, cardio-vascular disease drugs, and hepatitis drugs under the Asio name. Its products comprise Levodopa, Tabellae Sarcandrae, Rotandine Sulfate, Corydalis Saxicola Bunting, and Ethacridine Lactate injection. The company was formerly known as China Baicaotang Medicine Limited and changed its name to China BCT Pharmacy Group, Inc. in March 2010. China BCT Pharmacy Group, Inc. is headquartered in Liuzhou, the People's Republic of China.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-06-20 )

Largest Industry Peers for Pharmaceutical Retailers

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
ALBHF Alibaba Health Information Tec..

N/A

USD29.27B 542.50 70.16
RADLY Raia Drogasil S.A

N/A

USD8.89B 84.14 4.34
CLCGY Clicks Group Limited

N/A

USD4.83B 34.98 1.11
ZRSEF Zur Rose Group AG

N/A

USD4.09B N/A N/A
SDGCF Sundrug Co.,Ltd

N/A

USD3.81B 16.60 0.08
FFLWF Fire & Flower Holdings Corp

N/A

USD0.29B N/A 11.91
DRVD Driven Deliveries, Inc

N/A

USD0.06B N/A N/A
RXMD Progressive Care, Inc

N/A

USD0.03B N/A 17.28
HADV Health Advance Inc

N/A

USD0.01B N/A N/A
HEWA HealthWarehouse.com, Inc

N/A

USD8.78M 56.67 N/A

ETFs Containing CNBI

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Pharmaceutical Retailers)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 888.00% 100% A+ 96% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 888.00% 100% A+ 96% A
Trailing 12 Months  
Capital Gain 997.78% 87% B+ 94% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 997.78% 87% B+ 94% A
Trailing 5 Years  
Capital Gain 868.63% 90% A- 89% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 868.63% 90% A- 89% B+
Average Annual (5 Year Horizon)  
Capital Gain 108.57% 76% C 81% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 108.57% 76% C 81% B-
Risk Return Profile  
Volatility (Standard Deviation) 321.54% 35% F 18% F
Risk Adjusted Return 33.77% 53% F 59% F
Market Capitalization 1.88M 41% F 17% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Pharmaceutical Retailers)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 0.16 100% A+ 97% A+
Price/Book Ratio 0.01 100% A+ 96% A
Price / Cash Flow Ratio -0.20 63% D 58% F
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity 9.94% 70% C- 70% C-
Return on Invested Capital 17.31% 73% C 81% B-
Return on Assets 5.78% 85% B 86% B
Debt to Equity Ratio 0.08% 50% F 79% C+
Technical Ratios  
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta -3.75 100% A+ 96% A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to earnings

The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.